IR 820 dye encapsulated in polycaprolactone glycol chitosan: Poloxamer blend nanoparticles for photo immunotherapy for breast cancer

In the present study, we have fabricated biocompatible and biodegradable monodisperse IR 820 encapsulated<br>polycaprolactone (PCL) glycol chitosan (GC): Poloxamer blend nanoparticles (PP-IR NPs) for imaging and effective<br>photo-immunotherapy. IR 820 has been used as an imaging and photothermal agentwhereas glycol chitosan<br>(GC) as an immunostimulatory agent. The combination of IR 820, poloxamer, and GC can be used effectively for<br>photoimmunotherapy for cancer, drug-resistant and TNF-α resistant estrogen positive breast cancer. PP-IR NPs<br>are stable in aqueous solution. The uniform size of 100–220 nm with a high zeta value of +38 ± 2 mV led<br>them to accumulate in cancer cells. Laser treatment did not affect the morphology of PP-IR NPs as observed<br>under the transmission electron microscope (TEM). In vitro cytotoxicity studies onMCF-7 cells showed enhanced toxicity upon laser treatment. Further, we validated the cell death by reactive oxygen species (ROS) production.Our studies thus showed that PP-IR NPs are effective in suppressing metastatic cancer as the combinational therapy leads to the formation of apoptotic bodies in MCF-7 cells.